These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11369625)

  • 21. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
    Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
    Zimmerman TM; Harlin H; Odenike OM; Berk S; Sprague E; Karrison T; Stock W; Larson RA; Ratain MJ; Gajewski TF
    J Clin Oncol; 2004 Dec; 22(23):4816-22. PubMed ID: 15570084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
    Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
    Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
    Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
    Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.
    Lancet JE; Rosenblatt JD; Karp JE
    Semin Hematol; 2002 Jul; 39(3 Suppl 2):31-5. PubMed ID: 12214291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Farnesyl transferase inhibitors in clinical development.
    Caponigro F; Casale M; Bryce J
    Expert Opin Investig Drugs; 2003 Jun; 12(6):943-54. PubMed ID: 12783599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
    Kurzrock R; Cortes J; Kantarjian H
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
    Caraglia M; D'Alessandro AM; Marra M; Giuberti G; Vitale G; Viscomi C; Colao A; Prete SD; Tagliaferri P; Tassone P; Budillon A; Venuta S; Abbruzzese A
    Oncogene; 2004 Sep; 23(41):6900-13. PubMed ID: 15286715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
    Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
    J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A; Gray LA; Reeder T; Schroeder G; Kaufmann SH
    Leukemia; 2003 May; 17(5):849-55. PubMed ID: 12750696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.
    Ochiai N; Uchida R; Fuchida S; Okano A; Okamoto M; Ashihara E; Inaba T; Fujita N; Matsubara H; Shimazaki C
    Blood; 2003 Nov; 102(9):3349-53. PubMed ID: 12842991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.
    O'Meara SJ; Kinsella BT
    Br J Pharmacol; 2004 Sep; 143(2):318-30. PubMed ID: 15339863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
    Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
    Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
    Reichert A; Heisterkamp N; Daley GQ; Groffen J
    Blood; 2001 Mar; 97(5):1399-403. PubMed ID: 11222386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
    Rao S; Cunningham D; de Gramont A; Scheithauer W; Smakal M; Humblet Y; Kourteva G; Iveson T; Andre T; Dostalova J; Illes A; Belly R; Perez-Ruixo JJ; Park YC; Palmer PA
    J Clin Oncol; 2004 Oct; 22(19):3950-7. PubMed ID: 15459217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.